search
Back to results

Anfibatide Phase 1 Clinical Trial in Healthy Volunteers

Primary Purpose

Coronary Heart Disease, Coagulation Disorder

Status
Completed
Phase
Phase 1
Locations
Study Type
Interventional
Intervention
Anfibatide
Sponsored by
Lee's Pharmaceutical Limited
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Coronary Heart Disease

Eligibility Criteria

18 Years - 28 Years (Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • 1) Healthy volunteers, aged 18-28 years, male and female were included, age difference less than 10 years;
  • 2) Body weight: with body mass index (BMI) between 19-24, difference less than 10kg in the same group, BMI=body weight(kg)/height2;
  • 3) Past medical history: no history of heart, liver, kidney, digestive tract, nervous system and metabolic disorder, or ulcer, significant hemorrhage, without the history of drug allergy and postural hypotension;
  • 4) Medical examinations: with normal results in overall examinations (including heart rate, blood pressure, auscultation of heart and lung, palpation of liver and spleen, hepatic and renal function, hematology, coagulation function, urine analysis, stool analysis and occult blood test, electrocardiogram);
  • 5) Have not received any medications within 2 weeks before the study;
  • 6) Willing to participate in the study and give a signed informed consent form after understanding the study procedures and potential adverse reactions of the study product.

Exclusion Criteria:

  • 1) History of HBV or HCV infection;
  • 2) Addicted to smoking or alcohol;
  • 3) Women during pregnancy, lactation or menstrual period;
  • 4) Past history of hemoptysis, bloody stool, bleeding spots in the skin and mucous membrane, or hemorrhagic tendency (find themselves prone to bleeding in gums, nose, skin and mucous membrane, or hemoptysis);
  • 5) History of active bleeding (such as peptic ulcer, hemorrhoids, active tuberculosis, subacute bacterial endocarditis, etc);
  • 6) Blood platelet count less than 150×109;
  • 7) Trauma history (e.g., craniocerebral trauma) recently;
  • 8) Past history of unexplained syncope or convulsion;
  • 9) History of organic or psychogenic disease or the disabled;
  • 10) Persons who were unlikely to participate in the study (such as the infirm) in the investigator's opinion;
  • 11) Have donated blood or experienced blood collection in other trials within 3 months.

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm 3

    Arm 4

    Arm 5

    Arm 6

    Arm 7

    Arm 8

    Arm 9

    Arm 10

    Arm 11

    Arm Type

    Experimental

    Experimental

    Experimental

    Experimental

    Experimental

    Experimental

    Experimental

    Experimental

    Experimental

    Experimental

    Experimental

    Arm Label

    Single dose gourp 1

    Single dose group 2

    Single dose groups 3

    Single dose group 4

    Single dose group 5

    Single dose group 6

    Single dose group 7

    Single dose group 8

    Multiple dose group 9

    Multiple dose group 10

    Multiple dose group 11

    Arm Description

    Anfibatide injection at the concentration of 0.33μg/60kg in healthy volunteers

    Anfibatide injection at the concentration of 0.66μg/60kg in healthy volunteers

    Anfibatide injection at the concentration of1.0μg/60kg in healthy volunteers

    Anfibatide injection at the concentration of 1.5μg/60kg in healthy volunteers

    Anfibatide injection at the concentration of 2.0μg/60kg in healthy volunteers

    Anfibatide injection at the concentration of 3.0μg/60kg in healthy volunteers

    Anfibatide injection at the concentration of 4.0μg/60kg in healthy volunteers

    Anfibatide injection at the concentration of 5.0μg/60kg in healthy volunteers

    Give intravenous injection of 3μg as the first dose and after 1.5 hours, infusion of the study product 0.12μg/h for 24 hours

    Give intravenous injection of 3μg as the first dose and immediately infusion of the study product 0.12μg/h for 24 hours.

    Give intravenous injection of 5μg as the first dose and immediately infusion of the study product 0.12μg/h for 24 hours

    Outcomes

    Primary Outcome Measures

    Safety endpoints
    To investigate the number of adverse events in patients with single or multiple intravenous injection/infusion of Antiplatelet

    Secondary Outcome Measures

    Area Under Curve (AUC)
    To observe area under curve characteristics of Anfibatide in single or multiple dose groups

    Full Information

    First Posted
    April 25, 2012
    Last Updated
    April 26, 2012
    Sponsor
    Lee's Pharmaceutical Limited
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT01588132
    Brief Title
    Anfibatide Phase 1 Clinical Trial in Healthy Volunteers
    Official Title
    First Assessment of the Glycoprotein Ib-IV-V Complex Antagonist Anfibatide in Healthy Human Volunteers
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    April 2012
    Overall Recruitment Status
    Completed
    Study Start Date
    September 2010 (undefined)
    Primary Completion Date
    March 2011 (Actual)
    Study Completion Date
    March 2011 (Actual)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Principal Investigator
    Name of the Sponsor
    Lee's Pharmaceutical Limited

    4. Oversight

    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    In this 94 healthy subjects Phase I clinical trial, we assess the clinical profile of Anfibatide, a specific glycoprotein Ib antagonist. This study represents the first clinical evidence that Anfibatide exhibits strong anti-platelet effects, excellent reversibility, and low bleeding potential in healthy human subjects.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Coronary Heart Disease, Coagulation Disorder

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Phase 1
    Interventional Study Model
    Single Group Assignment
    Masking
    ParticipantCare ProviderInvestigator
    Allocation
    Randomized
    Enrollment
    94 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    Single dose gourp 1
    Arm Type
    Experimental
    Arm Description
    Anfibatide injection at the concentration of 0.33μg/60kg in healthy volunteers
    Arm Title
    Single dose group 2
    Arm Type
    Experimental
    Arm Description
    Anfibatide injection at the concentration of 0.66μg/60kg in healthy volunteers
    Arm Title
    Single dose groups 3
    Arm Type
    Experimental
    Arm Description
    Anfibatide injection at the concentration of1.0μg/60kg in healthy volunteers
    Arm Title
    Single dose group 4
    Arm Type
    Experimental
    Arm Description
    Anfibatide injection at the concentration of 1.5μg/60kg in healthy volunteers
    Arm Title
    Single dose group 5
    Arm Type
    Experimental
    Arm Description
    Anfibatide injection at the concentration of 2.0μg/60kg in healthy volunteers
    Arm Title
    Single dose group 6
    Arm Type
    Experimental
    Arm Description
    Anfibatide injection at the concentration of 3.0μg/60kg in healthy volunteers
    Arm Title
    Single dose group 7
    Arm Type
    Experimental
    Arm Description
    Anfibatide injection at the concentration of 4.0μg/60kg in healthy volunteers
    Arm Title
    Single dose group 8
    Arm Type
    Experimental
    Arm Description
    Anfibatide injection at the concentration of 5.0μg/60kg in healthy volunteers
    Arm Title
    Multiple dose group 9
    Arm Type
    Experimental
    Arm Description
    Give intravenous injection of 3μg as the first dose and after 1.5 hours, infusion of the study product 0.12μg/h for 24 hours
    Arm Title
    Multiple dose group 10
    Arm Type
    Experimental
    Arm Description
    Give intravenous injection of 3μg as the first dose and immediately infusion of the study product 0.12μg/h for 24 hours.
    Arm Title
    Multiple dose group 11
    Arm Type
    Experimental
    Arm Description
    Give intravenous injection of 5μg as the first dose and immediately infusion of the study product 0.12μg/h for 24 hours
    Intervention Type
    Drug
    Intervention Name(s)
    Anfibatide
    Intervention Description
    To investigate the safety and tolerability of single intravenous dose of Antiplatelet Thrombolysin for Injection of 0.33,0.66,1.0,1.5,2.0,3.0,4.0,5.0μg (body weight 60kg) in healthy volunteers. To investigate the safety and tolerability of continuous administration of three dose regimen: ① give intravenous injection of 3μg as the first dose and after 1.5 hours, infusion of the study product 0.12μg/h for 24 hours. ② give intravenous injection of 3μg as the first dose and immediately infusion of the study product 0.12μg/h for 24 hours. ③ give intravenous injection of 5μg as the first dose and immediately infusion of the study product 0.12μg/h for 24 hours.
    Primary Outcome Measure Information:
    Title
    Safety endpoints
    Description
    To investigate the number of adverse events in patients with single or multiple intravenous injection/infusion of Antiplatelet
    Time Frame
    24 Hours
    Secondary Outcome Measure Information:
    Title
    Area Under Curve (AUC)
    Description
    To observe area under curve characteristics of Anfibatide in single or multiple dose groups
    Time Frame
    Predose, 0,1,2,3,4,6,8,12,24,48,72,96 Hours

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Maximum Age & Unit of Time
    28 Years
    Accepts Healthy Volunteers
    Accepts Healthy Volunteers
    Eligibility Criteria
    Inclusion Criteria: 1) Healthy volunteers, aged 18-28 years, male and female were included, age difference less than 10 years; 2) Body weight: with body mass index (BMI) between 19-24, difference less than 10kg in the same group, BMI=body weight(kg)/height2; 3) Past medical history: no history of heart, liver, kidney, digestive tract, nervous system and metabolic disorder, or ulcer, significant hemorrhage, without the history of drug allergy and postural hypotension; 4) Medical examinations: with normal results in overall examinations (including heart rate, blood pressure, auscultation of heart and lung, palpation of liver and spleen, hepatic and renal function, hematology, coagulation function, urine analysis, stool analysis and occult blood test, electrocardiogram); 5) Have not received any medications within 2 weeks before the study; 6) Willing to participate in the study and give a signed informed consent form after understanding the study procedures and potential adverse reactions of the study product. Exclusion Criteria: 1) History of HBV or HCV infection; 2) Addicted to smoking or alcohol; 3) Women during pregnancy, lactation or menstrual period; 4) Past history of hemoptysis, bloody stool, bleeding spots in the skin and mucous membrane, or hemorrhagic tendency (find themselves prone to bleeding in gums, nose, skin and mucous membrane, or hemoptysis); 5) History of active bleeding (such as peptic ulcer, hemorrhoids, active tuberculosis, subacute bacterial endocarditis, etc); 6) Blood platelet count less than 150×109; 7) Trauma history (e.g., craniocerebral trauma) recently; 8) Past history of unexplained syncope or convulsion; 9) History of organic or psychogenic disease or the disabled; 10) Persons who were unlikely to participate in the study (such as the infirm) in the investigator's opinion; 11) Have donated blood or experienced blood collection in other trials within 3 months.

    12. IPD Sharing Statement

    Citations:
    PubMed Identifier
    34083615
    Citation
    Li BX, Dai X, Xu XR, Adili R, Neves MAD, Lei X, Shen C, Zhu G, Wang Y, Zhou H, Hou Y, Ni T, Pasman Y, Yang Z, Qian F, Zhao Y, Gao Y, Liu J, Teng M, Marshall AH, Cerenzia EG, Li ML, Ni H. In vitro assessment and phase I randomized clinical trial of anfibatide a snake venom derived anti-thrombotic agent targeting human platelet GPIbalpha. Sci Rep. 2021 Jun 3;11(1):11663. doi: 10.1038/s41598-021-91165-8.
    Results Reference
    derived

    Learn more about this trial

    Anfibatide Phase 1 Clinical Trial in Healthy Volunteers

    We'll reach out to this number within 24 hrs